Skip to main content
A simple hysterectomy is considered a safe option for low-risk early-stage cervical cancer patients and improves quality of life.

A simple hysterectomy is considered a safe option for low-risk early-stage cervical cancer patients and improves quality of life.

The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.

More >>
CIHR funding announced for CCTG PR25

CIHR funding announced for CCTG PR25

The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.

More >>
 CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement

CCTG NE2 trial successfully funded by CIHR

​The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.

More >>
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial

CIHR has announces funding for the TACtful cell therapy trial

CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.

More >>

Planned trials


MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML


Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials


Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)


Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)


Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy


Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer


Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)


NEEDS: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed)


Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)


CALMS: Combination Therapy with Luspatercept in Lower Risk MDS


Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma


STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Tumours


Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes


Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Participants with Painful Bone Metastases


Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT


STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study


Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25


SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma


MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Recently activated


Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial

More >>


Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma

More >>


Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma

More >>


OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

More >>


A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial

More >>


Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

More >>


Androgen Suppression Combined With Elective Nodal Irradiation and Dose Escalated Prostate Radiotherapy Treatment (ASCENDE-SBRT)

More >>
CCTG is recruiting for a Patient Representative to support the Genitourinary Committee

CCTG is recruiting for a Patient Representative to support the Genitourinary Committee

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Genitourinary Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gynecology Disease Site Committee, the Gynecology Disease Site Executive Committee, and the CCTG Patient Representative Committee.

More >>
Patient Representative Suzanne Wood

Welcome to Patient Representative Suzanne Wood

CCTG would like to extend a warm welcome to Patient Representative Suzanne Wood who will be supporting the GI disease site committee. Suzanne is from Toronto and was diagnosed with Stage IV Colon cancer in July 2022.

More >>
Welcoming new Patient Representative Haydn Bechthold

Welcoming new Patient Representative Haydn Bechthold

CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.

In 2021, at the age of 22, Haydn Bechthold received a stage 3C rectal cancer diagnosis, followed by the identification of Lynch syndrome. Having endured symptoms for over four years before his diagnosis, Haydn recognized the evident gaps in care for young adult cancer patients. This diagnosis abruptly halted his soccer career in Europe, yet it sparked a new passion for patient advocacy.

More >>
David McMullen CCTG patient rep

CCTG Patient Representative David McMullen honoured with 2023 CCRA award

The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

More >>


Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

N Engl J Med 388: 2159 - 2170, 2023
Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;

More >>

Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial (ONLINE)

International Journal of Radiation Oncology*Biology*Physics , 2023
Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;

More >>

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial (ONLINE)

The Oncol , 2023
Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;

More >>

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

N Engl J Med 388: 1645 - 1656, 2023
Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;

More >>

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Cancers 15: 1823, 2023
Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;

More >>

Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6

Supportive Care in Cancer 31: 256, 2023
Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;

More >>